AU2013395662B2 - 2- (5- (N- (4 -fluorophenyl) carbamoyl) pyrimidin- 2 - ylsulfanylmethyl) -4- (trifluoromet hoxy) phenyl) boronic acid - Google Patents

2- (5- (N- (4 -fluorophenyl) carbamoyl) pyrimidin- 2 - ylsulfanylmethyl) -4- (trifluoromet hoxy) phenyl) boronic acid Download PDF

Info

Publication number
AU2013395662B2
AU2013395662B2 AU2013395662A AU2013395662A AU2013395662B2 AU 2013395662 B2 AU2013395662 B2 AU 2013395662B2 AU 2013395662 A AU2013395662 A AU 2013395662A AU 2013395662 A AU2013395662 A AU 2013395662A AU 2013395662 B2 AU2013395662 B2 AU 2013395662B2
Authority
AU
Australia
Prior art keywords
compound
formula
dose
group
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013395662A
Other languages
English (en)
Other versions
AU2013395662A1 (en
Inventor
Dean Y. Maeda
Aaron D. Schuler
John A. Zebala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntrix Biosystems Inc
Original Assignee
Syntrix Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntrix Biosystems Inc filed Critical Syntrix Biosystems Inc
Publication of AU2013395662A1 publication Critical patent/AU2013395662A1/en
Application granted granted Critical
Publication of AU2013395662B2 publication Critical patent/AU2013395662B2/en
Priority to AU2019203931A priority Critical patent/AU2019203931B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
AU2013395662A 2013-08-02 2013-08-02 2- (5- (N- (4 -fluorophenyl) carbamoyl) pyrimidin- 2 - ylsulfanylmethyl) -4- (trifluoromet hoxy) phenyl) boronic acid Active AU2013395662B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019203931A AU2019203931B2 (en) 2013-08-02 2019-06-05 2- [5- [n- (4 -fluorophenyl) carbamoyl] pyrimidin- 2 - ylsulfanylmethyl] -4- (trifluoromet hoxy) phenyl] boronic acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/053376 WO2015016938A1 (en) 2013-08-02 2013-08-02 2- [5- [n- (4 -fluorophenyl) carbamoyl] pyrimidin- 2 - ylsulfanylmethyl] -4- (trifluoromet hoxy) phenyl] boronic acid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019203931A Division AU2019203931B2 (en) 2013-08-02 2019-06-05 2- [5- [n- (4 -fluorophenyl) carbamoyl] pyrimidin- 2 - ylsulfanylmethyl] -4- (trifluoromet hoxy) phenyl] boronic acid

Publications (2)

Publication Number Publication Date
AU2013395662A1 AU2013395662A1 (en) 2016-03-10
AU2013395662B2 true AU2013395662B2 (en) 2019-03-14

Family

ID=48998708

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013395662A Active AU2013395662B2 (en) 2013-08-02 2013-08-02 2- (5- (N- (4 -fluorophenyl) carbamoyl) pyrimidin- 2 - ylsulfanylmethyl) -4- (trifluoromet hoxy) phenyl) boronic acid
AU2019203931A Active AU2019203931B2 (en) 2013-08-02 2019-06-05 2- [5- [n- (4 -fluorophenyl) carbamoyl] pyrimidin- 2 - ylsulfanylmethyl] -4- (trifluoromet hoxy) phenyl] boronic acid

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019203931A Active AU2019203931B2 (en) 2013-08-02 2019-06-05 2- [5- [n- (4 -fluorophenyl) carbamoyl] pyrimidin- 2 - ylsulfanylmethyl] -4- (trifluoromet hoxy) phenyl] boronic acid

Country Status (12)

Country Link
EP (1) EP3027627B1 (https=)
JP (1) JP6509851B2 (https=)
KR (1) KR102107372B1 (https=)
CN (2) CN110200979A (https=)
AU (2) AU2013395662B2 (https=)
CA (1) CA2920172C (https=)
DK (1) DK3027627T3 (https=)
ES (1) ES2671927T3 (https=)
IL (1) IL243913A0 (https=)
MX (1) MX359556B (https=)
NO (1) NO3027627T3 (https=)
WO (1) WO2015016938A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
EP3027627B1 (en) * 2013-08-02 2018-01-31 Syntrix Biosystems Inc. 2-[5-[n-(4-fluorophenyl)carbamoyl]pyrimidin-2-ylsulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
JP2019135244A (ja) * 2019-04-03 2019-08-15 シントリックス・バイオシステムズ・インコーポレイテッドＳｙｎｔｒｉｘ Ｂｉｏｓｙｓｔｅｍｓ， Ｉｎｃ． ２−［５−［ｎ−（４−フルオロフェニル）カルバモイル］ピリミジン−２−イルスルファニルメチル］−４−（トリフルオロメトキシ）フェニル」ボロン酸
CN117954000A (zh) * 2023-12-29 2024-04-30 中山大学附属口腔医院 用于筛选对治疗牙周炎及认知障碍的化合物的方法及用途
WO2025193763A1 (en) * 2024-03-12 2025-09-18 Syntrix Biosystems Inc. Method for increasing survival in patients with cancer
EP4686469A1 (en) * 2024-07-31 2026-02-04 Dompé farmaceutici SpA Cxcl8 inhibitors for use in the treatment of diabetes-associated comorbidities

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1402730A (zh) * 1999-10-01 2003-03-12 阿斯特拉曾尼卡英国有限公司 新的噻唑并(4,5－d)嘧啶化合物
US20100210593A1 (en) * 2009-02-17 2010-08-19 Syntrix Biosystems, Inc. Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators
WO2012027289A1 (en) * 2010-08-23 2012-03-01 Syntrix Biosystems Inc. Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5475120A (en) 1990-11-02 1995-12-12 University Of Florida Method for the isolation and purification of taxol and its natural analogues
US5194635A (en) 1991-03-18 1993-03-16 Virginia Tech Intellectual Properties, Inc. Rearranged taxol compounds and method of using in testing of in vivo activity
US5416225A (en) 1992-03-30 1995-05-16 Sloan-Kettering Institute For Cancer Research Total synthesis of taxol
US5488116A (en) 1992-03-30 1996-01-30 Sloan-Kettering Institute For Cancer Research Total synthesis of taxol and analogues thereof
JPH07505887A (ja) 1992-04-17 1995-06-29 アボツト・ラボラトリーズ タキソール誘導体
US5440057A (en) 1993-08-20 1995-08-08 The Scripps Research Institute Access to taxol analogs
US5461169A (en) 1992-06-23 1995-10-24 The Scripps Research Institute Total synthesis of taxol and taxol analogs
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
US5478854A (en) 1992-10-01 1995-12-26 Bristol-Myers Squibb Company Deoxy taxols
US5411984A (en) 1992-10-16 1995-05-02 Virginia Tech Intellectual Properties, Inc. Water soluble analogs and prodrugs of taxol
WO1994013827A1 (en) 1992-12-07 1994-06-23 Michigan State University PROCESS FOR THE ISOLATION AND PURIFICATION OF TAXOL AND TAXANES FROM TAXUS spp
US5468769A (en) 1993-07-15 1995-11-21 Abbott Laboratories Paclitaxel derivatives
FR2707642B1 (fr) 1993-07-16 1995-10-13 Electricite De France Dérivés de polyéthers et d'hétérocycles pentacycliques, leurs polymères et leurs applications, notamment à la complexation d'ions métalliques.
US5405972A (en) 1993-07-20 1995-04-11 Florida State University Synthetic process for the preparation of taxol and other tricyclic and tetracyclic taxanes
US5565478A (en) 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5508447A (en) 1994-05-24 1996-04-16 Board Of Regents, The University Of Texas System Short synthetic route to taxol and taxol derivatives
US5489589A (en) 1994-12-07 1996-02-06 Bristol-Myers Squibb Company Amino acid derivatives of paclitaxel
EP3027627B1 (en) * 2013-08-02 2018-01-31 Syntrix Biosystems Inc. 2-[5-[n-(4-fluorophenyl)carbamoyl]pyrimidin-2-ylsulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1402730A (zh) * 1999-10-01 2003-03-12 阿斯特拉曾尼卡英国有限公司 新的噻唑并(4,5－d)嘧啶化合物
US20100210593A1 (en) * 2009-02-17 2010-08-19 Syntrix Biosystems, Inc. Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators
WO2012027289A1 (en) * 2010-08-23 2012-03-01 Syntrix Biosystems Inc. Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators

Also Published As

Publication number Publication date
AU2019203931A1 (en) 2019-06-27
CN105683202B (zh) 2019-05-10
WO2015016938A1 (en) 2015-02-05
JP6509851B2 (ja) 2019-05-08
MX2016001490A (es) 2017-01-05
AU2013395662A1 (en) 2016-03-10
KR20160051765A (ko) 2016-05-11
DK3027627T3 (en) 2018-05-22
IL243913A0 (en) 2016-04-21
NO3027627T3 (https=) 2018-06-30
MX359556B (es) 2018-10-02
KR102107372B1 (ko) 2020-05-07
CN110200979A (zh) 2019-09-06
CN105683202A (zh) 2016-06-15
AU2019203931B2 (en) 2020-06-11
EP3027627A1 (en) 2016-06-08
ES2671927T3 (es) 2018-06-11
CA2920172C (en) 2020-03-10
EP3027627B1 (en) 2018-01-31
JP2016525573A (ja) 2016-08-25
CA2920172A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
AU2019203931B2 (en) 2- [5- [n- (4 -fluorophenyl) carbamoyl] pyrimidin- 2 - ylsulfanylmethyl] -4- (trifluoromet hoxy) phenyl] boronic acid
USRE48547E1 (en) Aminopyrimidinecarboxamides as CXCR2 modulators
EP2942346B1 (en) Pyridinecarboxamides as cxcr2 modulators
US10046002B2 (en) Method for treating cancer using chemokine antagonists
US10561676B2 (en) Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10130645B2 (en) Use of thiopyrimidinecarboxamide for treating cancer
JP2019135244A (ja) ２−［５−［ｎ−（４−フルオロフェニル）カルバモイル］ピリミジン−２−イルスルファニルメチル］−４−（トリフルオロメトキシ）フェニル」ボロン酸

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)